SEC Form 4 · accession 0001412071-26-000006
Vistagen Therapeutics, Inc. · VTGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Shawn Singh
Officer — President and CEO · Director
Period of report
Jun 30, 2026
Accepted (ET)
Jul 2, 2026 · 4:16 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001411685
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 30, 2026 | A | 36,818 | $0.1921 | A | 54,846 | D | |
| Common StockF2 | holding | — | — | — | 20,875 | I | By The 1997 Singh Family Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents acquisition of shares under the Issuer's 2019 Employee Stock Purchase Plan, as amended (the "ESPP"), in a transaction exempt under Rule 16b-3 and Rule 16b-3(d). The Reporting Person purchased the maximum amount permitted under the ESPP.
- F2Shares held by The 1997 Singh Family Trust U/R/D 05/29/1997.